{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.3","upperLimit":"23.3","value":"17.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Overall Survival was the duration of time from the first day of study drug administration to the date of death from any cause.","dispersionType":"90% Confidence Interval","groups":[{"description":"SP-02L (darinaparsin for injection): Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days","id":"OG000","title":"SP-02L (Darinaparsin for Injection)"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis set included patients who fulfilled eligibility criteria and who took a tumor response assessment at least one time after the administration of SP-02L (darinaparsin for injection).","reportingStatus":"POSTED","timeFrame":"Survival follow-up was performed for 2 years from the date of first dosing of study drug. Maximum duration was 24.9 months.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}